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Abstract 
The development of homogeneous enzyme immunoassays (HEIA) for testosterone glucuronide 
(TG) and tetrahydrocortisone glucuronide (THEG) in urine are described. The proposed test 
system is based on the Ovarian Monitor homogeneous immunoassay system, established by J.B 
Brown and L.F. Blackwell et al. 1 as a simple, laboratory accurate, monitoring device for the 
measurement of estrone glucuronide (E1G) and pregnanediol glucuronide (PdG) as markers of 
the fertile phase during a womans menstrual cycle. This information can be used readily by 
women to identify their cyclical periods of fertility and infertility. 
The major testosterone metabolite in the urine of males, testosterone p-glucuronide, was 
synthesised by firstly preparing the glycosyl donor a-bromosugar and conjugating this with 
testosterone under standard Koenigs-Knorr conditions. 1H nmr studies confirmed that the 
synthetic steroid glucuronide had the same stereochemistry as the naturally occurring urinary 
testosterone glucuronide. 
Testosterone glucuronide and tetrahydrocortisone glucuronide conjugates of hen egg white 
lysozyme were prepared using the active ester coupling method in good yield. Unreacted 
lysozyme was successfully removed from the reaction mixture by a combination of cation-
exchange chromatography in 7 M urea and hydrophobic-interaction chromatography. S-
Sepharose chromatography allowed two of the major conjugation products in each steroid-
glucuronide reaction mixture to be isolated and characterised by MALDI mass spectrometry. All 
of the selected conjugates were found to be mono-acylated species, with the exception of one 
of the testosterone glucuronide conjugates, which was found to contain a mixture of mono- and 
di-substituted hen egg white lysozyme conjugates. Conjugates prepared in this way were 
tested for their suitability as signal generators in a homogenous immunoassay system for 
measurement of testosterone glucuronide and tetrahydrocortisone glucuronide in urine samples 
based on the already established Ovarian Monitor home fertility assay. 
Immunogens required for raising anti-steroid antibodies were also prepared using the active 
ester method to conjugate testosterone glucuronide and tetrahydrocortisone glucuronide to the 
carrier protein, bovine thyroglobulin. These immunogens were then used to raise anti-
testosterone glucuronide and anti -tetrahydrocortisone glucuronide antibodies in four New 
Zealand White rabbits. The antisera obtained over a number of months from each rabbit were 
screened for their ability to inhibit the lytic activity of the corresponding steroid glucuronide-
lysozyme conjugate. Although all the antisera showed the immunogens had stimulated the 
'Brown JB, Blackwell LF, Cox RI, Holmes JM and Smith MA (1988). Chemical and homogenous 
enzyme immunoassay methods for the measurement of estrogens and pregnanediol and their 
glucuronides in urine. Progress in Clinical and Biological Research 285:119-38. 
iii 
production of anti-steroid glucuronide antibodies, the antiserum titre was low, and meant that 
the volume of antiserum required to inhibit the lytic activity was high. Nevertheless, despite the 
low antiserum titres, the selected antisera could be used to produce good standard curves for 
testosterone with sensitivity close to that required for TG and an excellent standard curve for 
THEG. 
Potential applications of home assays for urinary testosterone glucuronide are in self-monitoring 
of testosterone levels in men undergoing long term testosterone supplementation for a 
diagnosed androgen deficiency or steroidogenic abnormality. Tetrahydrocortisone glucuronide 
is a major metabolite of cortisol, the main glucocorticoid produced by the body in response to 
stress and disease, and has potential as a biomarker for assessing therapies designed to reduce 
stress and for individuals suffering from stress related conditions such as hypertension and 
heart disease. 
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CHAPTER ONE 
Measurement of steroid hormones and the development of a 
multi-purpose home or on-site assay system based on the 
Ovarian Monitor 
1.1 Background to the study 
There is a growing realisation that non-invasive home, or point-of-care (for example at the 
patients medical centre), devices capable of delivering laboratory-accurate data for biomarkers 
of health and disease to lay individuals and health professionals will revolutionise medical and 
health practices. A biomarker can be defined as "any substance or process that could be 
monitored in tissues or body fluids that predicts or influences health or assesses the incidence 
or biological behaviour of disease" [1]. The best known biomarker is probably blood glucose for 
which there are already many semi-quantitative devices available used by diabetics to 
determine their blood glucose levels as a measure of control and immediate insulin 
requirements. Numerous other important biomarkers of health and disease states are also 
known and many of these are small molecule intermediates in biosynthetic pathways essential 
for maintain ing homeostasis. During metabolism detoxification of such compounds occurs in 
the liver, often by hydroxylation reactions involving cytochrome P450 enzymes and subsequent 
conjugation to glucuronic acid, and to a lesser extent sulphuric acid, in preparation for excretion 
via the renal system. This detoxification pathway also applies to many xenobiotic compounds 
such as ingested drugs. Thus, many of the important biomarkers are products of metabolism 
and are excreted in urine as glucuronide or sulphate conjugates. In principle the relatively high 
levels of urinary glucuronide metabolites constitute a battery of biomarkers that can be 
incorporated into non-invasive home or point-of-care urine tests if suitable methodology can be 
developed. 
All glucuronides have the same sugar structure that contains a reactive carboxyl functional 
group (shown in Figure 1.1) which can be conjugated with various reagents or proteins in 
(b) 
Figure 1.1 Examples of glucuronide metabolites : (a) tamoxifen-4-glucuronide [2], a major 
urinary metabolite of the potent antiestrogen tamoxifen which is routinely used in the 
t reatment of breast cancer and; (b) paracetamol glucuronide [3] . 
Chapter One: Introduction 2 
chemical reactions to produce biomaterials for assays. Clearly, reactions developed for one 
glucuronide will be applicable to all glucuronides albeit with some modifications, thus success 
with one system opens the way for a wide range of tests. This thesis is concerned therefore 
with developing a multi-purpose assay system based on biomarkers containing the generic 
glucuronide structure. 
1.2 Steroids as biomarkers of health and disease 
Apart from the monitoring of blood glucose to monitor insulin requirements by diabetics one of 
the most widely used class of biomarkers has been the steroids, particularly those that function 
as indicators of the key events in the human menstrual cycle. As well as their role in 
determining gender and fertility, there is increasing evidence that steroids have other important 
roles in health and disease. For example it has long been known that the human response to 
fear, stress and anxiety is also mediated by steroid hormones, and evidence of the potentially 
deleterious effects of chronic stress on our long term health is increasing . Individual 
susceptibility to disease may also be monitored using steroid biomarkers since many diseases 
may result in an overproduction, or underproduction of steroid hormones. 
Much interest also exists in developing new approaches to the identification of patients at high 
risk of disease recurrence particularly by using point-of-care or home testing. For instance, it 
has been established that androgens play a role in the pathogenesis of breast cancer [ 4,5]. In 
a large study of women with operable breast cancer (n = 113), urinary total testosterone levels 
in 24 hour samples were measured before surgery using gas chromatography to determine the 
"normal " excretion rate [6]. Further 24 hour samples were taken 40 days after surgery and 
thereafter once every six months at a specific time during the menstrual cycle for five years. In 
these women recurrence of breast cancer was associated with supra-normal urinary 
testosterone secretion. Thus, testosterone is a likely target as an important biomarker and 
monitoring of testosterone levels in women postmastecomy is especially important in the first 
five years following surgery since this has been identified as an important time frame during 
which relapse may occur [6]. 
A second interesting possibility is the major glucocorticoid hormone cortisol. The concentration 
of cortisol in the blood plasma is widely used as an indicator of stress [7,8, 9], and cortisol 
metabolites in the urine have been used as a measure of stress in the workplace. In a recent 
example the level of hypothalamic-pituitary axis (HPA) activation in doctors working the night 
shift at a hospital who typically experienced stress, fatigue and sleep deprivation was measured 
[10]. When off-duty, the excretion of the major cortisol urinary metabolites 
(tetrahydrocortisone + allotetrahydrocortisone + tetrahydrocortisol + allotetrahydrocortisol) in 
physicians was approximately the same as the non-physician controls. However, while on-duty 
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the sum of the major cortisol metabolites excreted in the urine increased by a factor of two 
compared to the off-duty excretion levels as shown in table 1.1 [10]. 
Table 1.1 Excretion rates (mg 24 h(1) of cortisol metabolites in on- and off-duty male physicians and in healthy 
men (controls) 
Physicians (n=S) 
Glucocorticoid Off-Duty On-Duty 
Mean± SD 
Tetrahydrocortisone 1.8 ± 0.7 
Tetrahydrocortisol 0.9 ± 0.3 
Allotetrahydrocortisol 0.4 ± 0.3 
Allotetrahydrocortisone 0.1 ± 0.6 
Main glucocorticoid metabolites§ 3.1 ± 1.2 
Ratio of cortisone/cortisol metabolites 1.5 ± 0.2 
* Comparing on- with off-duty physicians 
1Comparing off-duty physicians with controls 
4.0 ± 0.9 
2.0 ± 0.5 
0.7 ± 0.4 
0.1 ± 0.7 
6.8 ± 1.6 
1.6 ± 0.2 
Controls (n= 16) 
PValue * PValue* 
Mean ± SD 
0.0005 1.4 ± 0.6 0.05 
0.0005 0.8 ± 0.3 0.30 
0.001 0.5 ± 0.3 0.15 
0.002 0.2 ± 0.3 0.30 
0.0005 2.9 ± 1.1 0.30 
0.10 1.3 ± 0.4 0.05 
§ Tetrahydrocortisone + allotetrahydrocortisone + tetrahydrocortisol + allotetrahydrocortisol 
Cortisol metabolites may also be excreted and quantified in the feces of animals [8] . Recently 
this has been used as a more practical non-invasive alternative to urine testing as an indicator 
of stress in animal welfare studies and wildlife breeding programs [11,12]. 
1.3 General pathway for the biosynthesis of steroid hormones 
For the development of non-invasive techn iques to monitor steroid production, basic knowledge 
of the biosynthetic and metabolic pathways by which they are formed and excreted into 
biological fluids is necessary to aid in the choice of specific biomarkers. For example, many 
steroids are released from biosynthetic tissues in a pulsatile fashion, and the plasma 
concentration may increase by as much as SO to 100% depending on the time of sampling. 
Steroids circulating in the plasma may be either quickly cleared from the circulation and appear 
in the urine in the form of glucuronide and sulphate conjugates or metabolised into more potent 
forms by the target tissue. For example, cortisone may be metabolised to cortisol in the liver; 
testosterone may be metabolised to dihydrotestosterone in the prostate, or metabolised further 
to estrogens in reproductive tissues. 
The naturally occurring steroid hormones are all based on a fused tetracyclic hydrocarbon ring 
structure. Substituents, (e.g. carbonyl, hydroxy, methyl) located at specific positions within the 
steroid skeleton allow the steroids to be classified into three main chemical categories based on 
androstane, pregnane or oestrane ring structures (Figure 1.2). However the steroid hormones 
are more commonly classified by their biological activities into androgens, oestrogens, 
progestogens, corticosteroids and mineralocorticoids [13]. 
a) 18 
2 
3 
4 
12 
Tetracyclic steroid ring structure 
18 
b) 
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21 
Figure 1.2 Structures of (a) androstane, (b) oestrane and (c) pregnane ring systems. 
The major sites of steroidogenesis are the gonads (estrogens and androgens) and adrenal 
gland (corticosteroids, mineralocorticoids and androgens), although other organs such as the 
brain, liver and adipose tissue also play a significant role [14]. Recent experiments also suggest 
the nervous system produces steroid hormones [15]. The overall pathway for the synthesis of 
all steroid hormones is similar and tissue specific, cell-specific and even subcellular 
compartment specific differences in the expression of particular steroidogenic enzymes regulate 
the types and relative amounts of particular steroid hormones synthesised. All steroids are 
derived from pregnenolone which is itself synthesised from the precursor steroid cholesterol, as 
shown in Scheme 1.1. Cholesterol may be synthesised from acetate or derived from pools of 
cholesterol esters in steroidogenic tissues, but the preferred route for around 80% of the 
cholesterol used for steroid hormone production is via absorption of low density lipoprote in 
(LDL) cholesterol from the diet [15]. 
The first step in steroid biosynthesis involves the transfer of cholesterol to the inner 
mitochondrial membrane where it undergoes side chain cleavage of the c20_22 carbon bond by 
the cytochrome (CYP) P450 enzyme CYP11A (cholesterol desmolase) to form the 21 carbon 
steroid pregnenolone [16]. Delivery of cholesterol to the inner mitchondrial membrane is 
mediated by steroidogenic acute regulatory (StAR) protein, and forms the rate-limiting step of 
the reaction. 
The second subsequent side-chain cleavage of pregnenolone to form testosterone can occur by 
two distinct pathways. In the t-.s pathway, CYP17 catalysed hydoxylation of C17 and cleavage of 
the C1r C20 bond occurs before reduction of the C17 ketone group by 17~-hydroxysteroid 
dehydrogenase (17~-HSD) and oxidation of the A-ring by 3~-hydroxysteroid dehydrogenase t-.5-
t-. 4 isomerase (3~-HSD t-.5-t-. 4 isomerase). In the t-. 4 pathway this sequence is reversed; A-ring 
oxidation occurs before side chain cleavage and reduction of the C17 ketone group. The point in 
the pathway at which A-ring oxidation occurs depends upon the relative amounts of the 
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enzymes for the various substrates present and their compartmentalisation within the cell [17]. 
The predominant pathway in the testes and ovarian follicles, appears to be the t,.5 pathway 
(pregnenolone, dehydroepiandrosterone, androstenediol) whereas as the t,. 4 pathway 
(pregnenolone, progesterone, androstenedione) is dominant in the corpus luteum [18]. 
HO 
Cholesterol 
• StAR 1. 0 
2 
HO 
0 
2 
HO 
.. 
0 
0 
Enzymatic Steps: 
1. CYPllA: 20,22-hydroxylase 20, 22-desmolase 
2. 3p-hydroxysteroid dehydrogenase, D. 5 - D. 4 isomerase 
3. CYP17 (a) 17a-hydroxylase activity 
(b) 17,20-lyase activity 
4. CYP19: aromatase 
5. 17-ketosteroid reductase 
Progesterone 
Jai 0 
l 7a-hydroxypregnenolone 17a -hydroxyprogesterone 
0 
2 4 
HO 
Androstenedione Estrone 
.. 
2 4 
0 HO 
Testosterone Estradiol 
Androgens Estrogens 
Scheme 1.1 Biosynthesis of androgens and estrogens from cholesterol [19) 
Androstenedione and testosterone can be converted to their respective estrogens, estrone and 
estradiol by the cytochrome P450 aromatase enzymes in testes, ovary and extraglandular 
tissues of both sexes [17]. These conversions are irreversible and require the reduction of the 
C3 ketone functional group, removal of the C19 methyl group and aromatisation of the A-ring 
[20]. Although there is more androstenedione produced by the ovary than testosterone the 
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equilibrium of the 17~-hydroxysteroid dehydrogenase catalysed reaction ensures that most of 
the resulting ovarian estrogen is converted to estradiol [21) . 
1.4 Steroids as markers of the fertile window in the human menstrual cycle 
The central problem of fertility detection in humans, who lack an estrus symptom, is to identify 
the fertile window in a menstrual cycle. This is a variable period of days surrounding ovulation 
when an act of coitus may result in a pregnancy. Since the position of the day of ovulation is 
usually quite variable even within cycles from the same woman the fertile window will vary from 
cycle to cycle and from woman to woman. The length of the fertile window will also vary from 
cycle to cycle and from woman to woman. It is generally agreed that the ovum only survives 
for 8 - 12 hours after ovulation [22) but sperm survival in the female genital tract extends the 
fertile window by an amount determined by the sperm survival time. This is generally believed 
to average about 3 days [22) however pregnancies have been documented that seem to 
require a rare survival time of up to 6 or 7 days. Hence the maximum length of the fertile 
window can be 7 - 8 days (Brown et a/personal communication). What is needed to detect and 
monitor the fertile window is a biochemical marker for the beginning and end of this time. 
To achieve this goal it is first necessary to review the basic physiology of the human menstrual 
cycle. The menstrual cycle is controlled by a coordinated flow of chemical information between 
the ovary and the pituitary gland as shown in Figure 1.3. 
8 
FSH 
8 
Figure 1.3 Schematic diagram of pituitary-ovary communication . Abbreviations: BBT, 
basal body temperature; P, progesterone; PdG, pregnanediol glucuronide; E2, estradiol; 
ElG, estrone glucuronide; LH, luteinising hormone; FSH, follicle stimulating hormone. 
The major chemicals which carry the information are the pituitary hormones, follicle stimulating 
hormone (FSH) and luteinising hormone (LH) which carry information to the ovary and the 
ovarian hormones, estradiol (E2) and progesterone (P) which signal ovarian responses to the 
pituitary. Progesterone secreted from the ovary is rapidly cleared from the circulation by 
conversion to various metabolites. The major conjugated metabolite of progesterone excreted 
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in the urine is pregnanediol glucuronide (PdG) (about 20%) [23] which may be used as an 
index of ovarian progesterone production [24]. Once estradiol leaves the ovarian environment, 
it is oxidised by hydroxysteroid dehydrogenase enzymes in the liver to the less bioactive 
estrone. Estrone may either then re-enter the circulation or be rapidly metabolised further to 
estriol or conjugated in the liver to estrone glucuronide (ElG), which is excreted in large 
amounts in the urine. As well as being present in high quantities, estrone glucuronide is 
excreted rapidly and levels of ElG appear to be directly correlated to circulating levels of 
estradiol. This orchestrated chemical communication flow provides a means for 
"eavesdropping" non-invasively on the ovary to ascertain the state of follicular and corpus 
luteum development (and hence the state of fertility) at any time throughout the menstrual 
cycle. 
Although the best biochemical markers for the beginning and end of the fertile window are 
serum estradiol and progesterone their analysis requires several blood samples to be taken 
during the menstrual cycle which is generally considered an uncomfortable and invasive 
procedure. As noted above the urinary metabolites estrone glucuronide (ElG) and 
pregnanediol glucuronide (PdG) (shown in Figure 1.4) are widely accepted as alternative 
biomarkers of ovarian estrad iol and progesterone production respectively. The measurement of 
urinary metabol ites over serum ana lyses has the adva ntage that frequent specimen collection is 
easier and non-invasive with less stress to the subject [25]. In addition the urinary excretion 
rates are more closely related to ovarian secretion rates and integrate the pulsatile secretion of 
these hormones [25]. 
(a) 
COOH 
HO~ O 
HO~ 
OH 
(b) 
COOH 
HO~ O 
HO~ 
OH 
Figure 1.4 Structure of (a) estrone glucuronide (E1G) and (b) pregnanediol glucuronide (PdG). 
OH 
All of the available or foreseeable methods of detecting and predicting fertility depend on 
access to a procedure that detects one or more of the signals shown in Figure 1.3. It should be 
noted that no matter which method is being used the meaning of the underlying information 
remains the same. 
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1.5 Analysis of steroids and their glucuronides 
Although some hormones may be measured directly in biological fluids by a readi ly ava ilable 
assay, some information can be obtained only by measuring the ratio of biosynthetic precursors 
or hormone metabol ites. Information of this type is necessary for the diagnosis of 
endocrinological diseases which result from disruption of the normal pathways of steroid 
biosynthesis (e.g. adrenal hyperplasia [26]) or metabolism (e.g. polycystic ovaries [27] and 
apparent minera locorticoid excess [28]) . Blocks in biosynthesis or metabolism brought about 
by enzyme deficiencies or enzyme mutations can be read ily identified by increased levels of 
steroids intermediate in the biosynthetic pathway which would normally be present at low 
levels. Many assays used currently for the identification and quantification of steroid hormones 
are based on either bind ing assays or chromatograph ic methods. Typically immunoassays are 
used for the analysis of si ngle steroids, measured routinely in a cli nical setting and al low rapid, 
high-throughput, simple analyses. Assays for multiple or unusual steroids normally rely on 
chromatography methods. While affording high specificity and comparable sensitivity these 
techn iques are often more time consuming, labour intensive and often require specialised 
techn icians to operate. 
1.5.1 Chromatography techniques 
Chromatography based methods used for the analysis of urina ry stero ids can be divided into 
several categories, the most common being paper, th in layer (TLC), high performance liquid 
(HPLC) and gas chromatography (GC). HPLC and GC are the most common methods appl ied in 
routine assays, whereas paper and thin layer chromatography, although popular in the past are 
now only used in research and organic synthesis laboratories. The preferred detection system 
for steroid profiling by GC is a mass spectrometer, wh ich allows highly sensitive detection with 
excellent specificity. Recent reports also suggest that super-critical fluid (SCF) chromatography 
may have potential for the separation of steroids [29]. This method is based in the fact that 
some compounds, for example carbon dioxide, have a "critical " temperature and pressure 
above which their gaseous and liquid phases are no longer distinguishable. The fluids formed 
under these conditions have enhanced separating capacity by allowing a greater degree of 
interaction between stationary and mobile phases. However the instrumentation for SCF 
analysis is not yet widely available for routine analyses. 
While intact steroids and steroid conjugates can be assayed directly by GC using high 
temperature programmes, samples often require lengthy pre-treatment prior to analysis. For 
example, some steroids particularly corticosteroids, are thermolabile and must be chemically 
derivatised to prevent losses prior to analysis by GC. Steroid conjugates and columns are also 
subject to degradation under the high temperatures (350 °C) required to elute the steroid 
glucuronides [13]. As a result steroid conjugates are often hydrolysed using enzymes such as 
~-glucuronidase, to yield the free steroid which is then derivatised prior to analysis and the total 
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levels of steroid are reported (30]. This was the basis of the total estrogen method of Brown et 
al. which revolutionised our understanding of the human menstrual cycle in the second half of 
last century (31]. HPLC-MS systems can also be applied to the direct analysis of steroids in 
urine and plasma. The speed of analysis is often much faster since no derivatisation is required 
and the techn ique can be performed at room temperature allowing analysis of thermally 
unstable molecules, for example intact glucuronide and sulphate conjugates (32,33]. However 
HPLC-MS systems may not be as sensitive as GC-MS and radioimmunoassay (RIA) systems 
(discussed in section 1.5.2.1) and some buffered mobile phases may be incompatible with the 
mass spectrometer. Buffer salts may precipitate out around the interface, resulting in increased 
noise and necessitate frequent cleaning of the ionisation cone. 
1.5.2 Immunoassay techniques 
The binding of antibodies to specifically labeled antigens forms the basis of a range of assay 
techniques known collectively as immunoassays. The antigen may be attached to various labels 
including radioactive isotopes, as in radioimmunoassay (RIA), fluorescent compounds (in 
fluorescence polarization assays, FPIA) chemiluminescent molecules (CUA) or rely on enzymes 
which form the basis of a battery of tests known as enzyme immunoassays or enzyme-linked 
immunosorbent assays (ELISA). 
1.5.2.1 Radioimmunoassay 
A large number of journal reviews and texts have been published on the development of 
immunoassay techniques (34,35,36]. The basic principle of all immunoassays is that a labeled 
antigen (i.e. the compound of interest) competes with unlabeled antigen present in the sample 
(e.g. serum or urine) for a limited number of binding sites on an antibody. Radioimmunoassay 
(RIA) was the first immunoassay approach developed in the late 1950's (37] and employs 
radioactive isotopes, usually iodine or tritium, as the antigen label. The principal reactions 
involved in typical RIA systems are illustrated in Scheme 1.2. 
Ag* + Ab Ag*-Ab 
immune 
+ complex 
Ag 
1~ 
Ag-Ab 
immune 
complex 
Scheme 1.2 The principle reactions involved in radioimmunoassay 
(RIA). Abbreviations : Ag*, labeled antigen; Ab, antibody specific for 
the antigen; Ag, unlabeled antigen in the sample or standard. 
Chapter One: Introduction 10 
Appropriate volumes of antibody (Ab, which is specific for the antigen of interest), radiolabeled 
antigen (Ag*) and sample containing free antigen (Ag) are incubated together. Because the 
antibody concentration is limited, the antigen in the test sample must compete with the labeled 
antigen for the limited number of binding sites provided by the antibody molecules. Hence 
when equilibrium is reached, the greater the concentration of antigen present in the sample, 
the less labeled antigen that will be bound by the antibody. The next step in the assay involves 
separation of the antibody bound labeled antigen from the free labeled antigen. This is 
necessary since it is not possible to distinguish between free and bound radioactive label by the 
usual counting techniques. Separation is normally achieved by using procedures which 
separate the antigen-antibody complex while leaving the unbound antigen, both labeled and 
unlabeled, in solution. In practice, precipitation of the antigen-antibody complex from solution 
is most often achieved by adding a second antibody (which has been raised against the first 
antigen-binding antibody) to the reaction mixture. After separation, the radioactivity in either 
the free or antibody bound fraction of antigen is measured by radioactive counting. The 
amount of radioactivity observed is then compared to a standard curve constructed by assaying 
several samples conta ining known concentrations of unlabeled antigen. 
The major advantage of RIA is the high sensitivity and specificity obtainable with radiolabeled 
compounds. Since the radioactive label provides a distinct signal that shows little interference 
from other compounds in a biological fluid, radioimmunoassays have the capacity to detect 
compounds at levels of picomoles per litre or less. Although these systems are still in use for 
the detection of low levels of testosterone and cortisol in plasma [38], urine [39] and saliva [ 40] 
there are a number of disadvantages associated with the use of radiolabeled antigens. These 
include the disposal of the radioactive waste material, the limited half life and stability of some 
labeled antigens and the need for a specially equipped laboratory and expensive counting 
equipment to measure radioactivity at the assay end point. In addition the need to physically 
separate the bound and free labeled antigen makes the automation of RIA systems difficult and 
increases the cost of RIA analysis. However, radioimmunoassays can be established for any 
analyte providing a suitable specific antibody can be raised against the analyte. Many examples 
of radioimmunoassays for steroids and in particular estrone glucuronide and pregnanediol 
glucuronide have been reported [42,43,44]. 
1.5.2.2 Non-isotopic immunoassay techniques 
Since the introduction of RIA a variety of immunoassay systems using non-isotopic labels have 
been developed for the measurement of steroids and other small analytes in biological fluids. 
The most successful non-isotopic systems applied to the analysis of steroids include 
chemiluminescence and fluorescence immunoassay systems which employ either a luminescent 
or fluorescent tag (e.g. fluorescein or isoluminol) to label and measure the amount of bound 
and free antigen present in the sample. Both these methods have been applied to the 
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measurement of steroid and drug metabolites in body fluid [ 45,46,47]. The main advantages of 
chemiluminescent and fluorogenic substrates are their low cost, high sensitivity, long shelf-life 
of the lyophilised conjugates and the absence of radiation hazards [48]. The main 
disadvantages are associated with high background (signal to noise ratio) interference from 
endogenous substances in the sample matrix and light scattering, the need to use maximally 
purified water, and problems with temperature and pH variations which can affect the 
wavelength and intensity of the emitted light [ 49]. 
1.5.2.3 Enzyme immunoassays 
The development of immunoassay systems employing enzymes as the non-isotopic signal 
generating substances has proven to be a particularly popular alternative to RIA. Enzyme 
immunoassays (EIA's) utilise a) an enzyme labeled with antigen (called an enzyme conjugate), 
b) the ability of antibodies to discriminate between structurally similar antigens and c) the 
specificity and catalytic nature of the enzyme towards its substrate which facilitates signal 
amplification. Direct comparisons have shown that EIA's can be as sensitive or even more so 
than the corresponding RIA's, without most of the disadvantages associated with radiolabeled 
antigens [ 48,50]. 
Enzyme immunoassays can be divided into two broad groups, heterogeneous immunoassays 
and homogeneous immunoassays. Heterogeneous enzyme immunoassays (which include the 
enzyme linked immunosorbent assays or ELISA) are those in which the enzyme labeled with 
antigen is equally active in the antibody-bound and free state and therefore must be separated 
before any measurements can be made - as is the case with standard RIA. In homogeneous 
enzyme immunoassay systems the activity of the enzyme conjugate is extensively inhibited 
when antibody binds to the antigen. Thus, the amount of antibody bound enzyme label (which 
depends on the concentration of free antigen present) can be easily measured in solution by a 
simple kinetic measurement without the need for time consuming separation procedures. 
The first homogeneous enzyme immunoassay (HEIA) was performed by Rubenstein and co-
workers in 1972 [51] as an alternative to RIA and other heterogeneous immunoassays of the 
time. Rubenstein demonstrated that polyclonal antibodies specific to morphine could bind to a 
hen egg white lysozyme (HEWL) - carboxy methylmorphine conjugate and inhibit the enzyme 
activity by up to 98%. Lysozyme is one of the few enzymes that exhibits such extensive 
inhibition after binding to an anti-analyte antibody but enzymes such as malate dehydrogenase 
have been used in commercial EMIT (enzyme-multiplied immunoassay technique) by the SYVA 
company in California. Other homogeneous assay techniques exist which make use of a change 
in some property of the system, such as a change in fluorescence polarisation on binding to an 
antibody, and assays for estrone glucuronide and pregnanediol glucuronide have been 
described using these techniques [52,53]. 
Chapter One: Introduction 12 
1.5.3 Immunoassays for home monitoring - The Ovarian Monitor for estrone 
glucuronide and pregnanediol glucuronide 
It is clear that for home monitoring of any analyte, classical chromatographic assays and 
radioimmunoassays, and most non-isotopic assays are completely unsuitable. Most reported 
home assay systems for monitoring fertility have involved either lateral flow membrane assays 
(or immunochromatography assays) and the Ovarian Monitor which is based on Rubenstein's 
HEIA technique [51). For the Ovarian Monitor, a lysozyme-E1G or lysozyme-PdG conjugate 
must be prepared by combining hen egg white lysozyme (HEWL) with an appropriate activated 
carboxyl group reagent derived from the steroid glucuronide and isobutyl chloroformate (mixed 
anhydride method [51,54]) or dicycohexyl carbodiimide (active ester method [55]). The 
lysozyme conjugate is prepared by coupling of E1G or PdG ( via the carboxyl groups of the 
glucuronide moiety) with the amino groups of lysine residues on the surface of the enzyme. 
The lytic activity of the resulting conjugates in the immunoassay is determined by changes in 
light transmission of a suspension of the bacterial substrate Micrococcus /ysodeikticus 
( M. lysodeikticus). 
The synthetic steroid glucuronides are also used to prepare immunogens to raise the 
appropriate antibodies by coupling them (separately) to a protein carrier such as bovine serum 
albumin or thyroglobulin before injection into sheep or rabbits. A minimum of six months is 
usually required for the generation of high titre antibodies. 
The Ovarian Monitor home fertility system consists of two parts; the assay monitor and a 
specially designed plastic assay tube (Figure 1.5). The monitor itself consists of a cell holder 
maintained at 40 °C by a built-in thermostat, an automated timer, a 650 nm light source (a light 
emitting diode, LED) and a detector. The assay tube is placed inside the cell holder and 
maintained at 40 °C during the assay. The LED transmits light through the sample to a detector 
on the opposite side, which then displays the transmission result on the screen as a digital 
readout. The built-in timer is triggered by a magnetic switch activated by closing the cell holder 
lid and indicates the completion of each incubation step by a series of beeps. 
The plastic assay tube contains the assay components freeze dried at different levels on the 
tube wall. The antiserum and buffer salts are freeze dried at the bottom of the tube with a 
small glass bead to facilitate mixing, the lysozyme-hapten conjugate is immobilised near the 
centre of the tube and the Micrococcus lysodeikticus is immobilised near the top. This allows 
the assay components to be mixed in the appropriate order when sequential additions of urine 
and water are made. Separate assay tubes are required when assaying for E1G and PdG; E1G 
tubes contain anti-E1G antibodies and E1G-HEWL conjugate, while the PdG tubes contain anti-
PdG antibodies and PdG-HEWL conjugate. 
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Figure 1.5 The Ovarian Monitor (a) and an Ovarian Monitor assay tube (b), 
showing the position of the assay components freeze-dried to the tube. 
The Ovarian Monitor assay is based on the classic enzyme-multiplied immunoassay technique 
(EMIT) and takes place in three discrete steps as shown in Scheme 1.3. 
Step one: The antigen antibody reaction 
In the first step, 50 µL of time diluted urine is carefully added (via syringe) to the bottom of the 
assay tube. The tube is then placed inside the cell holder and allowed to incubate for five 
minutes to allow time for the buffer salts and antibody (Ab) freeze-dried on the bottom of the 
tube to completely dissolve. The Monitor signals the end of the incubation period by a series of 
beeps, after which the tube is removed and gently shaken horizontally for a count of twenty 
seconds to allow the steroid antigen (Ag, i.e urinary estrone glucuronide or pregnanediol 
glucuronide) to mix freely with the corresponding anti-steroid antibody (Ab). 
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Binding of the steroid to the antibody is rapid and effectively irreversible within the time frame 
of the assay [56]. Thus the level of antibody neutralisation, and hence the amount of free 
antibodies remaining at the end of the first step is directly proportional to the level of steroid in 
the urine. 
ElG or 
PdG in urine 
Step 1 
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antibody 
+ IAgl 
~acti,es;te 
active enzyme-steroid conjugate 
inactive immune complex 
~ ~ 
... 
DoO 0 o0 Micrococcus go g~°o~°o lysodetkticus 
o0 0 0 0 
turbid 
Step 3 
lysis of Micrococcuscell wall 
clear 
Scheme 1.3 Principle reactions in the Ovarian Monitor homogeneous enzyme immunoassay. 
Abbreviat ions used : Ag, antigen i.e urinary estrone glucuronide (ElG) or pregnanediol 
glucuronide (PdG); L, hen egg white lysozyme; Ab, anti-ElG or ant i-PdG antibody. 
Step 2: The antibody steroid glucuronide-lysozyme conjugate reaction 
In the second step, the lysozyme conjugate spot is dissolved by careful addition of 300 ~LL of 
distilled water by syringe to the assay tube. The tube is then gently shaken horizontally for 
another count of twenty seconds and returned to the Ovarian Monitor cell holder to incubate for 
a further period (PdG, 5 min; E1G, 20 min) . 
During the incubation step, the excess antibody which was not bound by urinary steroid in the 
first step is allowed to bind (again effectively irreversibly on the time scale of the assay) to the 
steroid-lysozyme conjugate. Binding of the steroid-lysozyme conjugate to its corresponding 
antibody inactivates the enzyme due to the antibody sterically blocking the access of the 
bacterial substrate to the active site and also partly by steric restriction of access to the 
transition state [57]. In this step the level of antibody binding is directly proportional to the 
amount of free antibody left at the end of the first step. Thus, the level of free enzyme 
conjugate remaining at the end of step two is proportional to the level of steroid glucuronide in 
the original sample of urine. 
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Step 3: The Micrococcus lysodeikticus reaction 
In the third and final step, the free conjugate remaining after the end of step two is given 
access to its natural substrate, the gram positive bacterium Micrococcus lysodeikticus. At the 
end of the incubation period in step 2 (signaled by a second series of beeps) the tube is 
removed from the cell holder and vigorously shaken for a count of twenty seconds to uniformly 
suspend the freeze dried M. /ysodeikticus cells and returned to the cell holder. Closing the cell 
holder signals the start of the enzyme assay and triggers the Monitor to record the initial 
transmission value, T0 min • In solution the suspended M. /ysodeikticus cells are large enough to 
scatter light and the solution appears opaque. However as the conjugate proceeds to lyse the 
Micrococcus cells by breaking the glycosidic bonds between sugar units in the polysaccharide 
component of the cell wall, the initially turbid solution begins to clear as the strength of the cell 
wall decreases and the cell col lapses. 
At the end of the assay period (PdG, 5 mins; ElG, 20 mins), the timer sounds and the 
difference between the final and initial transmission values (ElG, 6T 5 min-1; PdG, 6T 20 min-1) 
is left permanently flash ing on the LED screen. This change in transmission is a measure of the 
rate of lysis over the predefined assay period. Because only the free enzyme conjugate retains 
its lys is activity, the change in tra nsmission (or the rate of clea ri ng) is directly proportional to 
the amount of unbound conjugate remaining at the end of step two, which is in turn 
determined by the amount of stero id in the initial uri ne sample. 
Thus when the level of stero id glucuronide in the urine is low, most of the antibody is ava ilable 
for bind ing and inactivating the enzyme conjugate, resulting in a low rate of clearing of the 
turbid Micrococcus /ysodeikticus suspension . However as the concentration of steroid in the 
urine increases and becomes antibody bound, the proportion of antibody ava ilable for inhibit ing 
the conjugate activity decreases resulting in increased rates of lysis activity and higher rates of 
clearing. Thus, low levels of urinary steroid are associated with only small changes in light 
transmission (6T), whereas a high level of steroid generates a large change in transmission. 
Using a set of known concentrations a standard curve can be generated which relates the 
steroid glucuronide concentration to the observed change in transmission. A typical example of 
an optimised estrone glucuronide (ElG) curve relating the 24 hr molar excretion rates to the 
change in transmission over a twenty minute assay period (6T 20 min-1) is illustrated in Figure 
1.6. The curve shows the direct relationship between the lysis rate and the urinary steroid 
levels. The working range, i.e. the range of ElG excretion rates over which the curve is 
steepest and thus best able to discriminate between small changes in concentration is 25 - 410 
nmol ElG 24 h(1 (as indicated by the arrows). This range includes the physiological range of 
ElG concentrations expected in the urine of normally cycling women. The midpoint or point of 
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inflection (EC50 ) of the curve corresponds to the steroid concentration in the middle of the 
physiological range at N140 nmol ElG 24 h(1• 
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Figure 1.6 A standard curve for estrone glucuronide (ElG) generated using the Ovarian 
Monitor. The steepest section and thus most sensitive region of the curve corresponds to 
the range of ElG concentrations expected in the female urine during a normal menstrual 
cycle. 
The standard curve generated with the pre-dried assay tubes for any batch of antiserum and 
lysozyme steroid conjugate is extremely reproducible and eliminates the need to establish a 
new standard curve for each new analysis (unlike radioimmunoassay where a new standard 
curve must be generated for each new batch of samples analysed). Since the standard curve is 
programmed into the Monitor, the tubes are colour coded to the match the standard curve to 
which they belong. Using such a curve, the Ovarian Monitor (Mark IV) can convert the change 
in transmission value to a 24 hour molar excretion rate. Conversion to the twenty-four hour 
molar excretion rate is not absolutely necessary for home use (unless quantitative data is 
required) as it is the pattern of hormone excretion that is important for the determination of 
fertility status. For example each batch of PdG tubes is labeled with the t.T 5 min-1 value 
equivalent to a threshold value of 6.3 ~Lmol PdG 24 h(1. Thus the woman need only check if 
she has exceeded this change in transmission to know she has reached the late infertile days of 
the menstrual cycle. 
To monitor the changes in fertility status over the menstrual cycle the women can also plot their 
data as a change in transmission t. T vs. cycle day (Figure 1. 7). Hence a simple rate 
measurement gives a direct measure of the concentration of steroid glucuronide in the urine 
which allows couples either trying for, or trying to avoid pregnancy to determine what stage in 
the fertility cycle the women is. For example, Figure 1.7 shows that the beginning of fertility is 
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most likely on day 4 (6 days prior to the peak ElG day) as judged by the first rise in ElG above 
the preceding baseline [58]. The most fertile day is on day 11 (following the mid-cycle ElG 
peak day) and the end of her fertility for this cycle is given by the PdG rise on day 14 when the 
PdG threshold value is exceeded [25]. 
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Figure 1.7 Normal menstrual cycle obtained by a women using the Ovarian Monitor. 
Timed-diluted specimens of urine are essential for the assay to correct for fluctuations in urine 
volume which degrade the information and may render it uninterpretable in extreme cases. 
The urine may be collected overnight or during the day, provided that the period of collection is 
at least three hours [56]. The urine is diluted with tap water in a specifically graduated jug, 
such that the final dilution corresponds to the voiding of 150 ml h(1• This value is chose to 
represent the mean urine volume excreted of 3600 ml excreted in a 24 hour period. A portion 
of the diluted urine is then placed in a plastic tube and stored frozen if the test is not to be 
done immediately. 
The validity of the Ovarian Monitor home test system has been verified by numerous trials, 
including a World Health Organisation trial (WHO) [59], and has been accredited by the 
Australian National Association of Technical Authorities (NATA) for routine monitoring of the 
gonadotrophin treatment of infertile women [60] at the Royal Woman's Hospital, and the Mercy 
Hospital in Melbourne. The ElG assay has also been used since 1987 for monitoring estrogen 
responses during hyperstimulation on a large !VF program. 
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1.6 A multi-purpose self monitor for other urinary hormone metabolites 
It is obvious that the work carried out with the Ovarian Monitor should be applicable to a whole 
range of alternative steroid glucuronides providing that the requ ired conjugates and antibod ies 
can be synthesised. A range of assay tubes could then be developed using exactly the same 
techniques for other analytes of clinical or commercial interest. If the Monitor system were 
adapted so that it could recogn ise any assay tube introduced into it by appropriate coding then 
the same Monitor could measure a range of analytes in a home environment or in a point-of-
care setting. For testing the multi -Monitor proposa l, the major difficulty is to select an analyte 
for which there is likely to be a sufficient interest and demand for the test. 
1.6.1 Testosterone as a biomarker 
Male hypogonad ism may be defined as a failure of the testes to produce testosterone, 
spermatozoa or both. The most common causes of hypogonadism are associated with failure of 
the anterior pituitary gland, deficiencies in enzymes responsible for testosterone biosynthesis, 
and chromosomal abnormalities such as Kleinfelter's syndrome (47,XXY karyotype) wh ich 
affects ~ 1 in 400 ma les [61]. Chemotherapy or rad iation therapy may also result in long term 
testicular damage and reduced production of testosterone. Other conditions associated with a 
low testosterone in men include acute stress, alcoholism, obesity and chron ic or acute illness 
including HIV, leu kemia and ci rrhosis of the liver [47,62]. Plasma levels of free testosterone 
also show a steady decline with age, by approximately 1.2% per year starting at around age 40 
[63]. Age related testosterone decl ine may result in the loss of the diurnal rhythm of plasma 
testosterone secretion and cause a range of physical symptoms including a progressive 
decrease in muscle mass, loss of libido, erectile dysfunction, reduced sperm count and 
osteoporosis [6 1]. In adu lt females the opposite occurs; an excess of testosterone product ion 
is ind icative of a large number of abnormalities including polycystic ovaries, (as a result of 
defects in the enzymes that metabolise testosterone and cortisol) and ovarian tumours [64,65]. 
Increased levels of testosterone in women are also associated with hirsutism, and adrenal 
hyperplasia [47]. 
Over 4 million men in the USA diagnosed with a testosterone deficiency undergo replacement 
therapy, mostly by self-injection of testosterone every one to three weeks [66]. One of the 
major problems with this method of self-administration is that it is difficult to mimic the bodies 
production and management of testosterone levels. Injection introduces a high dose of 
testosterone, maintained for only the first few days a~er injection, returning to basal levels at 
the end of the treatment period. Testosterone administered by mouth is absorbed into the 
portal blood stream and promptly degraded by the liver so that only a small portion reaches the 
systemic circulation. More effective alternatives to androgen therapy involve administration of 
testosterone in a slowly absorbed form (dermal patches or a micronised oral preparation) or the 
administration of chemically modified analogs [67]. Recently a gel based formula containing 
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testosterone known as Androgel has become available in the USA (68]. To be administered 
once or twice a day, Androgel is thought to produce a more even plateau of testosterone 
concentration, thus avoiding the fluctuation in plasma levels resulting from injection. 
The safe use of testosterone replacement therapy relies on the monitoring of testosterone 
levels in biological fluid to assess the response to treatment, requiring multiple visits to the 
hospital or specialist. Such frequent visits may involve major disruption to family and working 
life, and may cost a considerable amount in travel and time away from work. In a clinical 
setting, testosterone is most frequently measured in the plasma. However since it is released 
from the testes in episodic spikes during the day, and is 25% higher in the morning than at 
night, at least 3 blood samples, taken at 20- to 40-minute intervals during the morning are 
required for measurement (69]. 
Home monitoring of testosterone production, performed by the patient, has the potential to 
overcome may of these problems by limiting the number of trips to a specialist clinic but still 
allow their dose regimes to be monitored safely. 
1.6.1.1 Testosterone biosynthesis 
In men, over 95 % of the testosterone is produced by the Leydig or interstit ial cells of the 
testes and is mainly controlled in adulthood by lutenising hormone produced by the pituitary 
gland [ 47]. In normal females, approximately half the testosterone produced is made by the 
ovaries; the remainder originates from the adrenal glands and conversion from estrogen in the 
periphery (70]. The pathway of testosterone biosynthesis from cholesterol has been illustrated 
already in Scheme l. l. 
In normal males an average of 5 - 6 mg of testosterone is secreted into the plasma per day 
[71]. For females this level is much lower at around 1.5 mg day (72]. In the blood, only 1 -
2% of the total testosterone circulates in the free state (unbound), the rest is bound to plasma 
binding proteins. Approximately 45% is bound with high affinity to a ~-globulin called sex 
hormone-binding globulin (SHBG), 50% is loosely bound to albumin, and other 1 - 2% is bound 
to an a 2-globulin called corticosteroid binding globulin (CBG) (73]. SHBG has about a 1000 fold 
higher affinity for testosterone than albumin, but the concentration of albumin is so much 
higher that the binding capacities of both proteins is considered to be similar (17]. For many 
years, only the free testosterone fraction was regarded as the biologically active portion 
available for entry into cells and binding to androgen receptors. It is now widely accepted that 
protein-bound testosterone can dissociate in the capillary bed and nearly all the albumin bound 
testosterone is available for tissue uptake in vivo so that the bioavailable testosterone in men is 
about half the total (equal to the free plus albumin bound fraction) (74,75]. 
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In adult males testosterone production shows diurnal variation, with the highest levels in the 
early morning, followed by a progressive fall throughout the day, reaching the lowest levels in 
the evening and during the first few hours of sleep (Figure 1.8). Peak and lowest values may 
differ by approximately 15%, although more pronounced differences are sometimes observed 
[76). 
s~-------------------------. 
... 
~ 
E 7 
Cl 
C 
QJ 
C 
0 
... 
QJ 
..., 
~ 6 
..., 
Ill 
QJ 
..., 
Ill 
E 
Ill 
-a 5 
24:00 04:00 
Young men (mean age = 25.2) 
Old men (mean age = 71) 
08 :00 12:00 16:00 20:00 24:00 
time (hours) 
Figure 1.8 Diurnal pattern of testosterone levels in plasma [77]. 
1.6.1.2 Biological activity of testosterone 
Testosterone that is not bound to plasma proteins diffuses out of capillaries and into target as 
well as non-target cells. Despite being the major steroid hormone produced by the testes, 
testosterone has few direct actions; instead, it serves as a circulating precursor (or pro-
hormone) for formation of the more potent Sa-reduced metabolite dihydrotestosterone (DHT) . 
In the target cells testosterone and DHT bind to the same high-affinity androgen receptor, and 
the hormone-receptor complexes attach to DNA response elements to initiate biologic responses 
(shown schematically in Figure 1. 9). These include the regulation of gonadotropin secretion by 
the hypothalamic-pituitary system, initiation and maintenance of spermatogenesis, and control 
of the male sex-drive [17). 
Alternatively, a variety of tissues including the testes, brain, breast and adipose tissue can 
metabolise testosterone and its immediate precursor androstenedione into estrogens. Estrogen 
formation is catalysed by the cytochrome P450 enzyme CYP19 (aromatase), which converts 
testosterone into estradiol and androstenedione into estrone (see Scheme 1.1). These 
metabolites, particularly estradiol, are biologically active and may act locally by binding to 
estrogen receptors in the tissues in which they are formed or re-enter the plasma. 
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The role of estrogens in male physiology is complex and not completely understood, but is 
thought to include acceleration of the pubertal growth spurt, accrual and maintenance of bone 
density, a role in male sexual drive, and an influence on gonadotropin secretion [17]. In 
addition, estrogens may enhance androgen activity by increasing the number of androgen 
receptors in the prostate. In turn androgens appear to act as weak antiestrogens by preventing 
the binding of estrogen to the estrogen receptor [17]. 
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Figure 1.9 Schematic diagram of androgen action . Testosterone, secreted by the testis, 
binds to the androgen receptor in a target cell either directly or after conversion to 
dihydrotestosterone (DKT). DHT binds more tightly than testosterone. The major 
actions of androgens (shown on the right of the diagram) are either mediated by 
testosterone (solid lines) or by DHT (broken lines) (17]. 
1.6.1.3 Hepatic metabolism of testosterone 
As for estradiol and progesterone, inactivation and excretion of testosterone and DHT occurs 
primarily in the liver, although metabolic enzymes are also present in other organs including the 
gut and kidneys [13]. Hepatic metabolism of testosterone also serves to increase the water 
solubi lity of the steroids by conjugation to glucuronic acid or sulphates, which facilitates their 
excretion in the urine as explained for E2 and P4 (section 1.4). Unconjugated steroids that are 
filtered by the kidney are largely reabsorbed [19]. 
The enzymatic reactions involved in hepatic metabolism are the same for androgens and 
corticosteroids, all containing a conjugated M ,3-keto moiety on the A-ring [13]. Oestrogens on 
the other hand, have an aromatic A-ring and are not substrates for the enzymes in these 
pathways [78]. The major reactions involved in the hepatic metabolism of testosterone include: 
(a) irreversible reduction of the A-ring across the 4-5 double bond from either the a (catalysed 
by Sa-reductase) or p (catalysed by sp-reductase) side of the A-ring. This step yields two 
isomers which differ in the orientation of the Cs hydrogen between the fused A and B rings. 
The Sa-metabolites have trans fused rings, which are essentially planar and similar to the 
parent steroids whereas the cis sp fused rings are more skewed. (b) The 3a,Sa/P reduced 
steroids are substrates for 3a-hydroxysteroid dehydrogenases which catalyse reduction of the 
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3-keto group to form 3a,Sa- and 3a,5~-tetrahydrosteroid metabolites which are then (c) rapidly 
conjugated to sulphates or glucuronic acid and excreted. The conjugates are more soluble in 
water and have a much lower affinity for plasma binding proteins than did the parent steroid, 
with glucuronides having the lowest affinity of all [13). The 3a,5~-reduced products of 
androstenedione are also substrates for 17~-hydroxsteroid dehydrogenase (17~-HSD) enzymes 
as shown in Scheme 1.4. 
In principle any of the range of testosterone metabolites present in the urine as glucuronides 
could serve as a urinary biomarker for serum testosterone production in humans. However, the 
stereospecific reductions which occur in vivo, while not impossible in vitro, nevertheless require 
a significant amount of synthetic effort. In the absence of information on the relative levels of 
these possible biomarkers in urine it seems sensible, at least at this stage of development, to 
focus on testosterone glucuronide as the urinary marker. It is relatively easy to synthesise and 
is expected to be excreted into the urine of males in significant amounts. 
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1.6.2 Cortisol and its metabolites as biomarkers of stress and disease 
Although there is some variation in the way that "stress" is defined, common among these 
definitions is that stress is a process in which environmental demands tax or exceed individuals' 
adaptive capacities, contributing to biological and psychological changes that may place them at 
risk for illness [79). 
While cortisol activation in response to stress is protective in the short term, the chronic or 
extreme activation may have long-term negative consequences. Cortisol stimulates the immune 
system and counteracts inflammatory and allerg ic reactions at normal levels but can suppress 
the immune system at excessive levels or when prescribed therapeutically in a synthetic drug 
form [80). Whereas hypercorticolism is associated with diseases characterised by 
immunosuppression and reduced ability to fight infections, including HIV [81,82,83] it may also 
increase susceptibility of developing chronic inflammatory disease, autoimmune disease and 
other diseases characterised by inflammation [80]. Hypercortisolism has also been associated 
with arthritis, multiple sclerosis and all types of cancer [83] and is the primary symptom of 
Cushing's disease [84]. Cortisol excess may also lead to insulin resistance, 
hypercholesterolemia and hypertriglyceridemia, thereby contributing to the development of 
adult onset diabetes, hypertension and heart disease [85,86]. 
Recently, the suggestion has been that elevated cortisol levels are in fact the causative agent of 
disease and the results have been presented at an International Conference [83). For example, 
it has been proposed that HIV stimulation induces the adrenal gland to produce elevated levels 
of cortisol and that elevated cortisol is, by itself, capable of inducing all of the symptoms and 
opportunistic infections encountered in AIDS [87]. Also, evidence has been presented which 
suggests that high levels of cortisol play a role in Alzheimer's disease, memory loss, shrinking of 
the brain and aging [88). The more conventional view is that the elevated cortisol levels are 
associated with other underlying mechanisms and are indicative rather than causative. For the 
purposes of this discussion it does not matter which view is correct since the high levels of 
cortisol can be used as a diagnostic tool in either case and appropriate strategies taken to 
alleviate the underlying conditions. There is also evidence that cortisol levels are of diagnostic 
importance for athletes; in particular elite women athletes who may face menstrual cycle 
disturbances [89]. 
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1.6.2.1 Cortisol biosynthesis 
The synthesis of cortisol from cholesterol shown in Scheme 1.5 occurs exclusively in the adrenal 
cortex via a series of reactions catalysed by cytochrome P450 (CYP) and various short chain 
dehydrogenase enzymes. These enzymes are located in either the lipophillic membranes of the 
smooth endoplasmic reticulum (ER) or the inner mitochondrial membrane. As the series of 
enzymatic reactions to convert cholesterol into cortisol proceeds, the steroid intermediates 
shuttle between the membranes of the two organelles [19]. In humans, the necessary 
transformations from cholesterol to cortisol proceed as follows; cholesterol is imported into 
mitochondria and converted to pregnenolone by the cytochrome P450 enzyme, CYPl lA as 
described for ElG and PdG in section 1.3. Pregnenolone is then transferred to the ER, where a 
17a -hydroxylase (CYP17) converts it to 17-hydroxypregnenolone. This is then a substrate for 
3~-hydroxysteroid dehydrogenase t:.5- t,,4 isomerase which catalyses oxidation at C3, resulting in 
a ketone functional group, and isomerisation of the double bond to form 17-
hydroxyprogesterone. A further hydroxylation in the smooth ER by a 21-hydroxylase (CYP21) 
converts 17-hydroxyprogesterone to 11-deoxycortisol. The latter is transferred back to the 
mitochondria and is converted to cortisol by an 11~-hydroxylase (CYPllBl). The final step is 
highly efficient, resulting in 98% conversion of 11-deoxycortisol to cortisol, which diffuses 
rapidly into the circulation without significant storage in the adrenal cortex [19]. An alternative 
pathway for cortisol biosynthesis exists in the mitochondria whereby oxidation of pregnenolone 
at C3 followed by isomerisation of the double bond forming progesterone occurs before the 
series of hydroxylations at C17 (17-OH progesterone), C21 (11-deoxycortisol) and finally at Cll 
in the ER terminating in cortisol [90]. 
Cortisol secretion under basal (i.e. non-stressed) conditions ranges from 8 mg/day to 25 
mg/day (22 - 69 ~1mol/day) with a mean of ~9.2 mg/day (25 ~1mol/day) [91]. In the plasma 
only 3 - 10% of circulating cortisol is in the free state. Approximately 80 - 90% is bound with 
high affinity to corticosteroid binding protein (CBG) and the remaining 5 to 10% is bound to 
albumin [19]. As for testosterone (see section 1.6.1.1) albumin has a much lower affinity for 
cortisol than CBG, but a much higher capacity. The dissociation of cortisol from albumin is 
more rapid, thus the albumin bound steroid is thought to be more readily available to the 
tissues than that bound by CBG. A third binding protein, a 1-acid glycoprotein can also bind 
cortisol, but appears to be only of minor importance to cortisol transport since it preferentially 
binds progesterone [19]. 
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Normally about 10 - 15 pulsatile bursts of cortisol are secreted into the plasma in a 24 hour 
period in adults [19,92). Like testosterone, cortisol levels in the blood show a clear diurnal 
rhythm. The levels are lowest around midnight and peak about half an hour after awakening as 
shown in Figure 1.10 [93). Peak levels on awakening may be 50 - 100% higher than the 
lowest levels. Hence this factor must be taken into account when designing assay protocols for 
cortisol or its metabolites. 
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Figure 1.10 Diurnal pattern of cortisol levels in plasma [78]. 
1.6.2.2 Biological activity of cortisol 
20:00 24:00 
Under basal condit ions, cortisol interacts mostly with high affinity mineralocorticoid receptors, 
which are important for normal homeostatic control of metabolic processes and fluid ba lance. 
However, when the hypothalamic-pituitary-adrenal (HPA) axis (those glands responsible for 
integrating the central nervous system and endocrine system) is activated during a stressful 
experience, cortisol levels can increase ten-fold and at these levels cortisol may bind to lower 
affinity glucocorticoid receptors in target tissues [94). 
Through its interaction with glucocorticoid receptors cortisol is hypothesised to promote short 
term survival in an acutely stressful event by: (1) increasing glucose and oxygen supply to 
skeletal muscles and heart and brain to facilitate flight and sharpen cognition to allow an 
appropriate behavioural response; 2) suppressing reproductive, immune and digestive functions 
to conserve energy; 3) promoting analgeisa and 4) activating the autonomic nervous system 
[95) . 
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Increasing levels of cortisol also act as a negative feedback signal to suppress further release of 
the hormones which stimulate cortisol production; corticotropin-releasing hormone (CRH) 
released from the hypothalamus and adrenocorticotropin-releasing hormone (ACTH) released 
from the pituitary (as shown in Figure 1.11). 
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Figure 1.11. Hypothalamic-pituitary axis (HPA) activation. When 
activated the HPA leads to the sequential release of hormones at 
each level of the axis, culminating in the release of cortisol. 
Through negative feedback inhibition, increasing levels of cortisol 
supress further CRH and ACTH release at the level of the 
hypothalamus and pituitary. Abbreviations : HPA, hypothalamic-
pituitary-adrenal; ACTH, adrenocorticotropin-releasing hormone; 
CRH, corticotropin-releasing hormone [78]. 
1.6.2.3 Hepatic metabolism of cortisol 
As noted earlier, the androgens and corticosteroids both contain a conjugated t.4,3-keto 
moiety on the A-ring and are metabolised by common pathways in the liver. The metabolic 
steps a), b) and c) described for hepatic metabolism of testosterone in section 1.6.1.3 also 
apply to cortisol, and the resulting cortisol metabolites are illustrated in Scheme 1.6. 
In addition, cortisol is a substrate for the enzyme 11~-hydroxysteroid dehydrogenase type 2 
(11~-HSD2) which catalyses the oxidation of the 11~-hydroxy group to form the inactive 
metabolite cortisone. Inactivation of cortisol by 11~-HSD2 occurs in the kidneys and other 
mineralocorticoid sensitive tissues [96) to protect mineralocorticoid receptors from illicit 
occupation by cortisol, which is present in concentrations in excess of the preferred ligand, 
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aldosterone [97]. Cortisone may then be metabolised by steps a), b) and c) as outl ined for 
cortisol or reactivated back to cortiso l by 11 ~-HSDl in several metabolic tissues including the 
liver, muscles, ad ipose t issue and brain [98,99]. Further reduction at the C20 posit ion in the 
side-chain of 3a, 5~-tetrahydro corticosteroids, by 20-dehydroxysteroid dehydrogenases can 
give rise to the corresponding 20a and 20~ isomers, namely cortols by reduction of cortisol and 
cortolones by reduction of cortisone [13]. Finally cleavage of the C17 side cha in may take place, 
producing 19 carbon metabol ites that have a ketone group at the C17 position, such as 11~-
hydroxyandrostenedione and 11-ketoetiocholanolone [19]. 
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Scheme 1.6 Metabolism of cortisol and cortisone [13]. 
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In the urine of normal subjects the 5~ metabolites predominate (5~:5a-tetrahydrocortisol 2:1). 
Approximately 50% of the secreted cortisol appears in the urine as tetrahydrocortisol (THF), 
allo-THF and tetrahydrocortisone (THE); 25 % as cortols and cortolones; 10% as 19 carbon 
steroids and 10% as cortolic and cortolonic acids. The remaining metabolites exist in the urine 
as unconjugated steroids; cortisol, cortisone, 6~- and 20a/~-metabolites of THF and THE 
[100,101]. Marked differences in the amount of total urinary cortisol metabolites excreted by 
age-matched males and females also exist. The reason for the difference is thought to reflect 
differences in the hypothalamic-pituitary adrenocorticol axis or primary differences in adrenal 
function [102]. Normally less than 1 % of cortisol is excreted unchanged in the urine of 
humans. Although this can be measured using RIA the levels are only of the order of 50 µg per 
day [15]. 
In a recent study by Yergey et al. [103], the metabolites of cortisol in urine were examined by a 
novel mass spectrometric procedure known as chemical reaction interface mass spectrometry or 
CRIMS. In this procedure the hydrolysed urinary metabolites of radiolabeled cortisol (9,12, 12-2H3 
cortisol) were measured in six human subjects and it was found that 5~-tetrahydrocortisone (THE) 
was the major metabolite constituting 42% of the total cortisol metabolites. Tetrahydrocortisone 
has three available hydroxy groups and hence this compound may appear in urine as a variety of 
glucuronides, sulphates or mixed sulphates and glucuronides. The 3a-glucuronide is the major 
metabolite and is excreted in amounts corresponding to about 5 mg per day [103] similar to 
pregnanediol-3a-glucuronide [25]. These levels are sufficient to make it possible to produce a 
rapid (5 minute) home and laboratory test for tetrahydrocortisone-3a-glucuronide, as a measure 
of total free cortisol by adaptation of our presently existing home test for the steroidal markers of 
the fertile phase of the human menstrual cycle [56,60]. 
1.7 Aims of the present study 
In summary the aims of the present study are: 
1. To expand the range of urinary steroid metabolites that can be measured using the Ovarian 
Monitor homogeneous immunoassay format currently used as a home monitoring device for 
determining the fertile period during a women's menstrual cycle. 
2. To prepare biomaterials for a testosterone glucuronide assay that can be used as a device 
for application to the urine of males as a biomarker of testosterone in men undergoing 
androgen replacement therapy. 
3. To prepare biomaterials for a tetrahydrocortisone glucuronide assay that could be used in a 
device for measuring stress. 
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4. To establish standard curves for the two urinary metabolites which are capable of 
measuring the physiological ranges of testosterone glucuronide and tetrahydrocortisone 
glucuronide. 
